Imaging the response of glioblastoma brain tumours to treatment with radiotherapy and chemotherapy by magnetic resonance and positron emission tomography.

Imaging the response of glioblastoma brain tumours to treatment with radiotherapy and chemotherapy by magnetic resonance and positron emission tomography. - Imaging the response of glioblastoma to treatment.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31106

Enrollment

Registered

2007-08-07

Start date

2007-06-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain cancer brain tumours

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Suspected intracranial glioblastoma on MRI eligible for operation Contrast enhancement after gadolineum on T1-weighted MRI Eligible for additional treatment with radiotherapy and chemotherapy after the operation Informed consent Adult, patients

Exclusion criteria

Exclusion criteria: Karnovsky score 70 years

Design outcomes

Primary

Measure	Time frame
Patients will be followed during the standard treatment. Before the neurosurgical operation, before and after the radiotherapy with concomitant chemotherapy, before the additive chemotherapy and after 2, 4 and 6 cycles of chemotherapy a MRI, MRS and FLT-PET scan will be made. The operation, radiotherapy and chemotherapy will not be postponed for the scans. After the operation a MRI scan is made within 72 hours. The response to therapy will be measured in progression free period, conventional radiological response and clinical response and be compared to the results of MRS and FLT-PET. After the normal treatment the FLT-PET and MRS scans will continued together with normal follow up MRI scan depending on the results of the first 40 weeks. Normally every 3 months. The endpoint for the study is defined as the last patients last visit.	—

Measure

Time frame

Patients will be followed during the standard treatment. Before the neurosurgical operation, before and after the radiotherapy with concomitant chemotherapy, before the additive chemotherapy and after 2, 4 and 6 cycles of chemotherapy a MRI, MRS and FLT-PET scan will be made. The operation, radiotherapy and chemotherapy will not be postponed for the scans. After the operation a MRI scan is made within 72 hours. The response to therapy will be measured in progression free period, conventional radiological response and clinical response and be compared to the results of MRS and FLT-PET. After the normal treatment the FLT-PET and MRS scans will continued together with normal follow up MRI scan depending on the results of the first 40 weeks. Normally every 3 months. The endpoint for the study is defined as the last patients last visit.

—

Secondary

Measure	Time frame
In the MR diagnostics protocol also diffusion- and perfusion weighted images are included. Changes in these images during the treatment will be correlated to the response of the tumour and compared to the results of the MRI, MRS and PET. Before the start of the additive chemotherapy the patients will be asked to answer questions about the burden and convenience of the study.	—

Countries

Netherlands

Outcome results